Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551820

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551820

Chemotherapy Treatment

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Chemotherapy Treatment Market to Reach US$31.5 Billion by 2030

The global market for Chemotherapy Treatment estimated at US$28.2 Billion in the year 2023, is expected to reach US$31.5 Billion by 2030, growing at a CAGR of 1.6% over the analysis period 2023-2030. Antimetabolites Drug Class, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Plant Derivatives Drug Class segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.7 Billion While China is Forecast to Grow at 3.6% CAGR

The Chemotherapy Treatment market in the U.S. is estimated at US$7.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 3.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.2% and 1.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Chemotherapy Treatment Market - Key Trends and Drivers Summarized

How Is Chemotherapy Treatment Shaping Cancer Care?

Chemotherapy treatment is a cornerstone of modern cancer care, playing a critical role in the fight against various types of cancer by using powerful drugs to target and destroy rapidly dividing cancer cells. This treatment can be used alone or in combination with other therapies such as surgery, radiation, or immunotherapy to shrink tumors, prevent cancer from spreading, and reduce the risk of recurrence. Chemotherapy has the ability to reach cancer cells throughout the body, making it particularly effective for cancers that have metastasized. Despite its side effects, which can include nausea, fatigue, and hair loss, chemotherapy remains an essential tool in oncology, offering hope to millions of patients by improving survival rates and, in many cases, achieving remission. The evolution of chemotherapy has also led to more personalized approaches, where treatments are tailored to the specific type and stage of cancer, as well as the patient’s overall health.

What Innovations Are Enhancing the Effectiveness of Chemotherapy Treatment?

Innovations in chemotherapy treatment are significantly enhancing its effectiveness through the development of targeted therapies, combination treatments, and advanced drug delivery systems. Targeted therapies represent a major advancement, allowing for drugs that specifically attack cancer cells with minimal damage to healthy tissues, thereby reducing side effects and improving patient outcomes. These therapies work by interfering with specific molecules involved in cancer cell growth and survival. Additionally, the use of combination therapies, where chemotherapy is paired with other treatment modalities like immunotherapy or hormonal therapy, has shown to be more effective in some cases by attacking cancer through multiple pathways. Advanced drug delivery systems, such as liposomes, nanoparticles, and antibody-drug conjugates, are also being developed to improve the precision of chemotherapy. These systems help concentrate the chemotherapy drugs in the tumor area, enhancing their efficacy while minimizing systemic exposure and side effects. These innovations are transforming chemotherapy into a more targeted, effective, and patient-friendly treatment option.

How Does Chemotherapy Treatment Impact Patient Quality of Life and Survival Rates?

Chemotherapy treatment has a profound impact on patient quality of life and survival rates, often making the difference between life and death for many cancer patients. While the treatment can be physically and emotionally challenging, its ability to shrink tumors, slow disease progression, and, in some cases, achieve complete remission can extend life expectancy and improve long-term outcomes. Advances in supportive care, such as anti-nausea medications and growth factors, have also improved patients' ability to tolerate chemotherapy, thereby enhancing their quality of life during treatment. Furthermore, the development of less toxic chemotherapy regimens and the use of precision medicine to tailor treatments have reduced the incidence of severe side effects, allowing patients to maintain better overall health and well-being throughout their cancer journey. Despite its challenges, chemotherapy continues to be a lifeline for many, offering the possibility of cure or control of cancer for extended periods.

What Trends Are Driving Growth and Innovation in Chemotherapy Treatment?

Several key trends are driving growth and innovation in chemotherapy treatment, including the rise of personalized medicine, advancements in molecular biology, and the integration of new technologies in drug development. Personalized medicine is increasingly influencing chemotherapy, as genetic profiling of tumors allows for more individualized treatment plans that are tailored to the specific genetic mutations present in a patient’s cancer. This approach increases the likelihood of treatment success and reduces unnecessary toxicity. Advances in molecular biology are also leading to the discovery of new drug targets and mechanisms of action, enabling the development of next-generation chemotherapy agents that are more effective and have fewer side effects. The integration of technology, such as artificial intelligence and machine learning, in drug development and patient monitoring is further accelerating innovation in chemotherapy by improving drug discovery, optimizing treatment protocols, and predicting patient responses to therapy. These trends are pushing the boundaries of what is possible in chemotherapy, leading to more effective and personalized cancer treatments that improve patient outcomes and quality of life.

Select Competitors (Total 41 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Jazz Pharmaceuticals Plc
  • Kura Oncology
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Oncology ;
Show more
Product Code: MCP24280

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Chemotherapy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Targeted Chemotherapy and Personalized Treatment Plans
    • Rising Global Cancer Prevalence and the Urgent Need for Effective Treatments
    • Integration of Chemotherapy with Immunotherapy and Other Modalities Enhancing Outcomes
    • Developments in Drug Delivery Systems to Reduce Side Effects and Improve Efficacy
    • Impact of Health Insurance Policies on Chemotherapy Access
    • Data-Driven Oncology: Utilizing Big Data to Inform Treatment Protocols
    • Challenges in Managing Multidrug Resistance in Cancer Therapy
    • Future Trends in Nanoparticles and Its Role in Chemotherapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chemotherapy Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antimetabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Plant Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Plant Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Plant Derivatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cytotoxic Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cytotoxic Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cytotoxic Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Chemotherapy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Chemotherapy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Chemotherapy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Chemotherapy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Chemotherapy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Chemotherapy Treatment by Drug Class - Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Chemotherapy Treatment by Drug Class - Percentage Breakdown of Value Sales for Antimetabolites, Plant Derivatives, Cytotoxic Antibiotics, Alkylating Agents and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!